Bottlenecks in HIV-1 transmission: insights from the study of founder viruses by Joseph, Sarah B. et al.
Bottlenecks in HIV-1 transmission: insights from the study of 
founder viruses
Sarah B. Joseph1,2, Ronald Swanstrom2,3,4, Angela D. M. Kashuba4,5, and Myron S. 
Cohen1,4,6
1Department of Microbiology and Immunology, University of North Carolina at Chapel Hill
2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
3Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill
4UNC Center for AIDS Research, University of North Carolina at Chapel Hill
5Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
6Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, 
Chapel Hill, North Carolina 27599, USA
Abstract
HIV-1 infection typically results from the transmission of a single viral variant, the transmitted/
founder (T/F) virus. Studies of these HIV-1 variants provide critical information about the 
transmission bottlenecks and the selective pressures acting on the virus in the transmission fluid 
and in the recipient tissues. These studies reveal that T/F virus phenotypes are shaped by 
stochastic and selective forces that restrict transmission and may be targets for prevention 
strategies. In this Review, we highlight how studies of T/F viruses contribute to a better 
understanding of the biology of HIV-1 transmission and discuss how these findings affect HIV-1 
prevention strategies.
HIV-1 is the retrovirus (genus Lentivirus) responsible for acquired immunodeficiency 
syndrome (AIDS). The virus replicates predominantly in CD4+ T cells, which produce virus 
that is readily and persistently detected in the blood and other bodily fluids. Most HIV-1 
transmission events worldwide are a result of heterosexual sex with an infected partner, and 
approximately 80% of heterosexual transmission events and infections are established from 
a single HIV-1 variant — termed the transmitted/founder virus (T/F virus) — as based on 
analyses of the complexity of the virus in the blood during the first several weeks of 
infection1–4. Shortly after transmission, HIV-1 populations in the blood of the newly 
infected individuals are largely homogenous and evolve in a manner consistent with 
exponential viral replication3, which allows for the genetic sequence of a T/F virus to be 
inferred as the same as the consensus sequence constructed from the viral population present 
early in infection3. In contrast to the homogeneous viral population observed in the 
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recipients shortly after transmission, there is typically a diverse viral population in the blood 
of infected donors, which indicates that there are one or more strong bottlenecks that result 
in the transmission of a single T/F virus (FIG. 1). Therefore, there is continued interest in 
understanding whether these bottlenecks are stochastic and restrict all viruses (for example, 
nonspecific barrier functions) or whether there are selective pressures favouring certain 
phenotypes in the T/F virus. Extensive efforts have been made to find viral phenotypes that 
correlate with transmission, as exploring these phenotypes may elucidate the biology of 
HIV-1 transmission and inform novel prevention approaches.
The selective pressures that shape the bottlenecks that lead to the transmission of a T/F virus 
can occur at different stages in the transmission cycle: in the donor variants at the site of 
transmission; during the transmission process of moving the virus particles from the donor 
to the site of infection in the recipient; with the infection of the initial cell in the recipient; or 
in the first few rounds of replication, during which inefficient viral spread might result in the 
infection being extinguished (FIG. 1). As the stochastic and selective forces that act at these 
different stages will differ based on the donor and recipient environment, there is unlikely to 
be a single phenotype or genetic sequence that is shared by all T/F viruses. Rather, 
phenotypes that increase the probability of transmission will be over-represented in T/F 
viruses. In this Review, we discuss the different bottlenecks that shape the transmission of 
T/F viruses, including the conditions that enhance or limit HIV-1 transmission, and the 
features of the viruses that are selected during transmission, highlighting how these findings 
have the potential to inform the development of biological interventions directed against 
HIV-1.
Transmission bottlenecks in the donor
Individuals chronically infected with HIV-1 have diverse viral populations in their blood, 
but that diversity can be reduced by bottlenecks that take place as viruses seed the genital 
tract (GT) and enter the transmission fluid (semen, cervicovaginal mucus (CVM) or rectal 
mucus) (FIG. 1).
Compartmentalization at the donor site of transmission
The migration of HIV-1 from the blood into the transmission fluid is likely to be greatly 
influenced by the trafficking of infected immune cells and/or free viruses from the blood 
into the GT and the rectum. This notion is consistent with an analysis of the env sequences 
of simian immunodeficiency virus (SIV) in male macaques, which showed that SIV 
populations that are present in the semen and tissues of the male GT are derived from the 
viral populations that are present in the blood5. However, it is also possible that viruses 
replicate locally in the GT. Therefore, the composition of viral populations at the site of 
transmission in the donor is likely to reflect a dynamic relationship between the trafficking 
of free virus from the blood, HIV-1-infected cells from the blood that release viruses into the 
GT, and the local replication of viruses in the GT.
Sustained replication in the GT can create genetically distinct, compartmentalized lineages 
of viruses (FIG. 2). The existence of compartmentalized lineages in the GT is somewhat 
surprising given the evidence for frequent, bidirectional trafficking of HIV-1 between the 
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blood and GT6, which is predicted to homogenize the populations in these two 
compartments. Nonetheless, compartmentalization in the GT of both males7–15 and 
females8,14–17 infected with HIV-1 has been reported. Notably, viral populations 
compartmentalized in the GT can include clonally amplified and/or diverse, GT-specific 
lineages (FIG. 2). The majority of these GT-specific lineages are clonally amplified in both 
males7,8 and females8,18,19. Furthermore, when sampled longitudinally, most clonally 
amplified GT-specific lineages are expressed transiently8,18.
These observations are consistent with a model in which inflammation, which is most 
commonly caused by a change in the viral, bacterial and/or fungal species present in the GT, 
especially following the acquisition of a sexually transmitted pathogen20, can drive HIV-1 
replication in the GT. In this model, GT inflammation, whether clinical or subclinical, may 
lead to bursts of virus production from a small cluster of T cells infected by a single virus, 
resulting in clonal viral amplification (FIG. 2). Inflammation may also create clusters of 
HIV-1-susceptible cells in the GT by recruiting these cells from the periphery, causing their 
local proliferation and activation in the GT. Furthermore, these newly recruited, HIV-1-
susceptible cells may amplify viral variants that exist in the GT and/or viral variants that are 
trafficked to the GT by infected T cells. In any case, as the inflammation resolves and the 
number of HIV-1-susceptible cells in the GT returns to pre-inflammation levels, the 
amplified viral variant is predicted to quickly decay.
In contrast to these clonally amplified viral lineages that are present in the GT, a few GT-
specific lineages have been observed to be moderately8 to substantially7 diverse in their 
genetic complexity (FIG. 2). These diverse lineages are produced through multiple rounds of 
isolated viral replication and evolution in the GT of males7 and females8. Although our view 
of clonally amplified GT viruses is that they typically represent transient lineages8,18, a 
longitudinal analysis of a female patient who had a moderately diverse, compartmentalized 
lineage showed that this diversity persisted in the GT over a period of 28 days8. The small 
number of observations of diverse GT compartmentalized lineages may reflect either that 
these lineages rarely arise or that they frequently arise but persist at lower abundance than 
clonally amplified variants. Furthermore, it is unknown whether these lineages represent 
viruses that have adapted to replicate in new target cells in the GT or viruses that are simply 
replicating independently in an area of the GT that is seldom reached by blood viruses.
Clonally amplified viruses in the GT would be predicted to have a transmission advantage 
owing to their higher frequency in the transmission fluid. However, a study of transmission 
pairs found compartmentalized variants in the GT of seven out of eight donors and showed 
that, at the time of sampling — which was between 2 and 12 weeks after the transmission 
event — the T/F viruses were minority (not clonally amplified) variants in the GT of each 
donor8. Without samples taken at the time of transmission (an impossible task), the 
possibility that the T/F variants were clonally amplified at the time of transmission cannot 
be ruled out, but these observations suggest that downstream bottlenecks may reduce or 
obscure any transmission advantage associated with viral frequency in the transmission 
fluid.
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The effect of compartmentalization on transmission is also complicated by the fact that viral 
populations in the GT can be further divided into free virus and cell-associated virus groups. 
Little is known about whether these forms are genetically distinct and whether they both 
contribute to transmission. One study of six men who have sex with men (MSM) 
transmission pairs suggested that each T/F virus was more similar to free viruses present in 
the seminal plasma of the donor than to viral DNA from the donor's seminal cells, which is 
consistent with sexual transmission typically occurring by transfer of cell-free virus21. 
However, a re-analysis of the viral sequences questioned this conclusion for technical 
reasons22. An additional study found some evidence of transmission of a cell-associated 
variant23 in humans, and studies of SIV-infected macaques have revealed that transmission 
can occur by vaginally inoculating females with either cell-associated24 or cell-free 
viruses25. Although both routes of infection are possible, infection studies in macaques 
almost exclusively use cell-free viruses and have proven that this route is highly effective, 
whereas there is relatively little evidence that cell-associated virus can be transmitted. This 
discrepancy could be due to technical challenges that make it difficult to illustrate 
transmission of cell-associated virus or due to cell-associated virus being a highly inefficient 
mode of transmission. This is an important issue for developing prevention strategies.
Selection in the transmission fluid
Selection in the transmission fluid is another possible bottleneck during the transmission 
cycle of HIV-1. For example, the transmission fluid may contain neutralizing antibodies or 
lectins that prevent some HIV-1 variants from being transmitted. Alternatively, some viruses 
may become trapped in the mucosal secretions.
The Env protein is expressed on the surface of HIV-1 particles and mediates target cell 
binding; however, its exposure at the surface of the virus also makes the Env protein a target 
of neutralizing antibodies. A great deal of effort has been put into examining env gene 
sequences and Env protein phenotypes in T/F viruses, trying to identify genetic or 
phenotypic evidence of selection during transmission. These studies have attempted to 
compare the T/F virus to the total donor population in linked transmission events or have 
compared T/F viruses with a surrogate population meant to approximate the donor 
population. After identifying a statistical relationship between a specific genotype or 
phenotype and transmission, researchers try to infer where in the transmission process the 
selective pressure occurred that skewed the viral population. The search for genetic variation 
has focused on identifying ‘signature sequences’ that are associated with increased 
transmission probability26.
One feature that has been observed in T/F viruses is their differential levels of glycosylation. 
For example, T/F viruses of HIV-1 subtypes A, C and D1,27–29 have fewer N-linked 
glycosylation sites encoded by their env gene, but this pattern is less obvious for subtype B 
T/F viruses27,30,31. Interestingly, the role of glycosylation in transmission may differ for 
men and women and may depend on the mode of viral transmission. A study of 
heterosexually transmitted subtype C viruses found that the bias towards transmission of low 
glycosylation viruses was particularly pronounced in female-to-male transmission, 
suggesting that female-to-male transmission either selects viruses with fewer glycosylation 
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sites or selects viruses lacking specific glycosylation sites29. A potential explanation for 
these observations is a model in which heavily glycosylated viruses are less likely to be 
sexually transmitted32,33 because they are more easily trapped in the transmission fluid or 
inhibited by agents present in the transmission fluid (FIG. 3). As intrapartum transmission 
requires a virus to interact with a transmission fluid (the CVM), this model would predict 
that intrapartum transmission also selects for T/F viruses with fewer glycosylation sites. 
Consistent with this prediction, viruses transmitted intrapartum display fewer glycosylation 
sites than those transmitted intrauterine, which is a mode of transmission that does not 
involve interaction of HIV-1 with the CVM34. Notably, although heavier glycosylation 
reduces the probability of sexual and intrapartum HIV-1 transmission, it may provide the 
virus with an evolutionary advantage at later stages of infection by increasing viral 
resistance to neutralizing antibodies29,32,33 through the establishment of a ‘glycan shield’, 
which is known to facilitate escape from neutralizing antibodies by obscuring viral 
epitopes35,36.
Despite the differences in glycosylation observed in T/F viruses, the examination of 
neutralization sensitivity to specific antibodies has not revealed consistent differences 
between T/F viruses and viruses present during chronic infection. This is somewhat 
surprising given that T/F viruses are generally less glycosylated and would be predicted to 
be more sensitive to neutralization. Consistent with this prediction, subtype B T/F viruses 
have been reported to be moderately more sensitive to neutralizing antibodies that target the 
CD4-binding site of Env37; however, this has not been seen with subtype C T/F viruses29. 
Similarly, one study observed that the Env proteins of subtype C T/F viruses are more 
sensitive to autologous donor antibodies1 compared with the average donor virus. However, 
several studies have shown that Env proteins from T/F viruses and Env proteins from 
viruses present at chronic stages of infection rarely differ in their sensitivity to heterologous 
antibodies1,29. If we consider sensitivity to heterologous antibodies as a probe for Env 
protein conformation, these data seem to indicate that there is no conformational difference 
between the T/F viruses and the typical viruses that are present in the donor. However, the 
observation of a difference in sensitivity to autologous antibodies between T/F viruses and 
the donor viruses that are present in the peripheral blood during chronic infection needs to 
be confirmed, and at the moment the significance of this difference is unclear.
Glycosylation can also affect viral binding by broadly neutralizing antibodies (BNAbs), as 
these antibodies can include a glycan as part of their epitope target (FIG. 3). For example, an 
analysis of sera from nine patients with strong BNAb responses to HIV-1 revealed that eight 
produced BNAbs with glycan-dependent epitopes38. Notably, loss of a glycosylation site 
can make a virus resistant to certain BNAbs that bind to glycans on the Env surface, such as 
2G12, PG9 and PG16 (REF. 36). Interestingly, the slight overall reduction in glycosylation 
of subtype C T/F viruses is mostly represented in lost glycosylation sites within the highly 
variable regions of Env, not the more conserved glycosylation sites that are recognized by 
these well-characterized BNAbs. This explains how T/F viruses can have fewer 
glycosylation sites than viruses isolated from subjects during chronic infection (about 7% 
fewer) yet T/F viruses are not, on average, more resistant to BNAbs that bind epitope targets 
that include conserved glycans29.
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Lectins may also select for under-glycosylated Env proteins during transmission (FIG. 3). 
Many lectins have been shown to bind glycans on the surface of the envelope glycoprotein 
gp120 and thus inhibit HIV-1 (or simian–human immunodeficiency virus (SHIV)) infection 
in cell culture, in ectocervical explants and in macaque models (reviewed in REF. 39). One 
of these lectins, the mannose-binding lectin (MBL), plays an important part in innate 
immunity by binding carbohydrates on the surface of many pathogens40 and activating the 
complement system. For example, lower MBL levels are associated with susceptibility to 
Streptococcus pneumoniae, Neisseria meningitidis and influenza A virus, as well as with the 
severity of hepatitis B infection (reviewed in REF. 40). Notably, genetic differences between 
donors in serum MBL levels have been shown to vary by more than 1,000-fold41. Studies 
examining the relationship between MBL levels in serum and HIV acquisition have reached 
different conclusions, with some studies suggesting that MBL is protective and others 
suggesting that it increases susceptibility to HIV-1 (REF. 40). To understand the role of 
MBL in HIV-1 transmission, it may be useful to examine whether MBL levels in genital 
secretions influence HIV-1 susceptibility. Interestingly, MBL is found at low concentrations 
in semen42, but whether MBL is present in CVM is unknown.
Another donor factor that could influence transmission is a peptide fragment of the semen-
derived protein prostatic acid phosphatase (PAP; also known as ACPP), which forms 
amyloid fibrils that capture HIV-1 and facilitate its attachment to target cells in the 
recipient43. These fibrils, termed semen-derived enhancers of virus infection (SEVI), have 
been shown to enhance HIV-1 infection in a dose-dependent manner44 in vitro. Similarly, 
semenogellin-derived amyloid fibrils in semen are also capable of enhancing virus 
attachment and entry45. The potential importance of a SEVI-like activity is also 
demonstrated by infectivity studies in cell culture-based assays, in which the inclusion of 
semen reduced the activity of several antivirals in blocking infectivity (with maraviroc — an 
antiretroviral agent developed to prevent HIV-1 infection by blocking the C–C chemokine 
receptor type 5 (CCR5) co-receptor46 — being a notable exception)47. Although semen-
derived amyloid fibrils enhance infection in vitro, less is known about their effects in vivo. 
For example, an analysis of the effect of SEVI on the transmission of SIVmac in macaques 
did not provide conclusive evidence for SEVI enhancing infection48, and there are currently 
no human data indicating that SEVI enhance transmission.
Additional donor effects increasing HIV-1 transmission
In addition to GT compartmentalization and to the selection of viral variants in the 
transmission fluid, other donor factors, such as the viral load at the time of transmission, 
may alter HIV-1 transmission rates. It has long been recognized that donors with higher viral 
loads in their blood49,50 and/or GT51,52 transmit HIV-1 more readily than donors with lower 
viral loads. This relationship is further supported by a recent study showing that initiation of 
antiretroviral therapy, which lowers viral loads, results in lower transmission rates49.
The concentration of HIV-1 in blood plasma and genital secretions can vary by several 
orders of magnitude owing to many factors, including concomitant viral, bacterial or 
parasitic infections that enhance (reviewed in REF. 53) or suppress54,55 replication of 
HIV-1. For example, confection with Neisseria gonorrhoeae is associated with elevated 
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concentrations of HIV-1 in the blood plasma of women56 and in semen57. N. gonorrhoeae 
produces heptose monophosphate, which stimulates an innate immune response that results 
in increased nuclear factor-κB (NF-κB)-mediated transcription of the HIV-1 long terminal 
repeats (LTR)58 as one mechanism that could affect the level of virus. Similarly, co-
infection with herpes simplex virus 2 (HSV-2) has also been associated with elevated 
concentrations of HIV-1 in genital secretions (reviewed in REF. 59), but the mechanistic 
relationship between HSV-2 infection and HIV-1 replication is still being investigated60. 
Nonetheless, a general inflammatory response and the influx of inflammatory cells into the 
GT as a result of HSV-2 co-infection are likely to be major factors in determining the HIV-1 
viral load. The effect that sexually transmitted infections (STIs) have on HIV-1 replication is 
further illustrated by observations that treating co-infected men for N. gonorrhoeae 
significantly reduces HIV-1 viral load in semen57 and treating co-infected women for 
HSV-2 significantly reduces HIV-1 viral load in genital secretions and blood plasma59.
Transmission bottlenecks in the recipient
The most severe bottleneck that occurs during transmission takes place in the GT of the 
recipient, where the viral diversity present in the transmission fluid is typically reduced to a 
single genotype, which initiates the systemic infection (FIG. 1).
Infection of target cells in the recipient genital tract
For an HIV-1 particle to initiate an infection, it must reach and infect subepithelial cells in 
the recipient GT, particularly CD4+ T cells. The ability to enter these cells is governed by 
the viral surface Env protein. When translated, the Env precursor protein is cleaved into two 
subunits, gp120 and gp41, which stay non-covalently associated as heterodimers. Three of 
these heterodimers are organized as a trimeric spike on the surface of the virion, with gp41 
being a transmembrane protein anchoring the trimer and gp 120 being exposed at the apex of 
the trimer and most distal to the viral surface. Viral entry is initiated when the CD4-binding 
site of gp120 of one or more trimers binds CD4 molecules on the surface of the host cell, 
which results in conformational changes that expose the co-receptor-binding site on gp120. 
This co-receptor-binding site then engages the CCR5 co-receptor or, in some cases, the C-X-
C chemokine receptor type 4 (CXCR4) co-receptor, which are expressed on the surface of 
the host cell. Co-receptor engagement causes the extracellular domain of gp41 to insert its 
amino-terminal fusion peptide into the host cell membrane, initiating the formation within 
gp41 of a six-helix bundle, which brings the host and viral membranes together to generate a 
fusion pore between the viral and host membranes that the viral capsid can use to enter the 
host cell61. Given the central part played by Env during viral entry, several Env-mediated 
phenotypes have been proposed to have a role in the infection of subepithelial target cells 
and to define the nature of the target cell in transmission.
The discovery of co-receptors for HIV-1 entry (REF 62) led to an understanding that the T/F 
virus typically uses CCR5 for entry, but the role of CD4 in defining the tar‑ get cell has only 
recently been clarified. In recent years, the ability of HIV-1 to infect cells expressing 
different levels of the entry receptor CD4 and its co-receptor CCR5 has been assayed using 
the Affinofile (receptor affinity–profiling) cell line, in which expression of CD4 and CCR5 
is under inducible control63. These assays have confirmed that the vast majority of blood-
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derived viruses use the CCR5 co-receptor but that they poorly infect cells expressing low 
levels of CD4 (REFS 29,64,65). CD4 is expressed at a high density on CD4+ T cells but at a 
much lower density on other CD4-expressing cells, such as monocytes and macrophages64. 
Thus, most blood-derived HIV-1 viruses can be termed ‘R5 T cell-tropic’. Similarly, HIV-1 
T/F viruses are nearly always R5 T cell-tropic (FIG. 4). Conversely, several studies have 
shown that T/F viruses are unable to efficiently infect macrophages64,66–69 or other cells 
expressing low levels of CD4 (REFS 29,64) (FIG. 4). For example, pseudotyped viruses 
made with env clones from 33 heterosexually transmitted T/F viruses were inefficient at 
infecting cells expressing low levels of CD4 (REF. 29). Similarly, these 33 subtype C T/F 
viruses29 and 55 subtype B T/F viruses3 all used CCR5 as the co-receptor, with only one 
virus being capable of also using the alternative co-receptor CXCR4 (that is, being ‘dual-
tropic’).
T/F viruses have also been shown to have unexpected features associated with the use of 
CCR5. For example, T/F env clones are less likely to be able to use a maraviroc-resistant 
form of CCR5 than chronically derived viruses29. This phenotype is clearly observed when 
cells express high levels of CCR5 (REFS 29,70) but not when cells express lower levels of 
CCR5 (REFS 29,65). These data are consistent with CCR5 existing in multiple 
conformations when expressed at high levels, and either resistant viruses using a novel 
maraviroc-bound form of CCR5 or CCR5 existing in conformations that maraviroc cannot 
bind but that some viruses can use for entry. Regardless of the specific mechanism, 
transmission seems to select for viruses that are more restricted in the use of CCR5 co-
receptor variants than blood-derived chronic viruses.
T/F viruses also differ from other HIV-1 viruses in their ability to incorporate Env protein in 
newly formed virions, and one study of infectious molecular clones (IMCs) of T/F viruses 
revealed that they produce viruses that contain twice as much Env protein as IMCs of 
chronically derived control viruses71. This is consistent with a study of subtype B env 
sequences showing that transmitted env genes are enriched for encoding a basic amino acid 
at position 12 in the Env leader sequence, which increases Env density on pseudoviruses72. 
Higher Env protein concentration may increase the probability that a virus attaches to and 
infects a target cell in the genital mucosa or rectum of the recipient.
T/F viruses also display enhanced binding to dendritic cells (DCs) and are subsequently 
transferred to T cells more efficiently than viruses derived from chronic infections71. This 
could facilitate efficient transport of T/F viruses from the epithelial surface to the stroma or 
to lymphoid tissue, where the virus can be presented to, and infect, T cells73. A study 
exposing human vaginal explants to HIV-1 found that T/F viruses efficiently bound DCs, 
which then transported the viruses through the mucosa and presented them to T cells74. 
Similarly, in vitro studies have shown that DCs are able to facilitate infection after being 
incubated with HIV-1 and then co-cultured with T cells75–78. These results suggest that DCs 
may facilitate HIV-1 infection of T cells during transmission, but there is little evidence that 
DCs themselves are productively infected79–81, consistent with their low density of surface 
CD4.
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Finally, studies of SIV transmission indicate that resting CD4+ T cells are the most abundant 
CD4-expressing cells in the subepithelial tissue before infection and are the earliest cells 
infected. However, once infected, resting CD4+ T cells produce fewer virus particles than 
activated T cells82,83. Furthermore, treatment of macaques with the antimicrobial agent 
glycerol monolaurate can suppress immune signalling in the female GT and prevent 
transmission of SIV, probably by inhibiting recruitment of T cells and DCs84. These 
observations suggest that recruiting T cells, and perhaps DCs, to the site of exposure 
enhances viral transmission and the establishment of systemic infection, which provides at 
least a partial explanation for why bacterial vaginosis85 and HSV-2 (REF. 86) infections — 
which result in the recruitment of immune cells to the site of infection — are associated with 
increased susceptibility to HIV-1.
Viral replication in the recipient genital tract
There is now strong genotypic and phenotypic evidence that transmission selects for viruses 
with higher replication rates. In a recent study87 of gag, pol and nef sequences from 137 
linked transmission pairs, donor sequences that more closely matched the cohort consensus 
sequence were more likely to be transmitted than were sequences that differed more from 
the consensus. This advantage is thought to arise because being more similar to the 
consensus sequence produces higher-fitness viruses with elevated infectiousness or burst 
size. The higher-fitness nature of the consensus sequence is supported by studies showing 
that when low-fitness cytotoxic T lymphocyte (CTL)-escape mutants 88–90 are transmitted, 
they often quickly revert to the consensus sequence at that site87,91–93. The emerging picture 
is that transmission occurs in a multiple-step process that probably involves stochastic 
bottlenecks that limit transmission of all viruses and selective bottlenecks that select for 
phenotypes such as reduced glycosylation and higher fitness (BOX 1; FIG. 3).
Bias towards transmission of higher-fitness variants reveals information about the 
environment in which transmission takes place. Such evolutionary change could be 
generated only if higher-fitness viruses have a higher probability of generating a systemic 
infection (that is, there is selection) and viruses replicating at the site of exposure differ in 
their fitness (that is, there is genetic variation). Higher-fitness viruses could be selected 
under multiple scenarios, which differ primarily in the number of viruses replicating at the 
site of transmission. For example, exposure to HIV-1 could result in the initial replication of 
multiple, heterogeneous viruses at the site of transmission, followed by a second stage in 
which only one virus establishes systemic infection. In this scenario, the virus with higher 
fitness would be successful and lower-fitness viruses would be lost. A prediction of this first 
scenario is that the multiple lineages that replicate initially at the site of transmission would 
occasionally give rise to viral recombinants, but deep sequencing viral populations during 
acute infection has not revealed recombinant genomes or rare genomes94,95 (but see REF. 
96). Therefore, if multiple viruses are indeed transmitted to new HIV-1 recipients, most are 
probably lost in the initial rounds of replication. In an alternative scenario, after exposure to 
HIV-1, no more than one virus replicates at the site of transmission and most replicating 
viruses do not generate systemic infection. In this case, when a systemic infection is 
established it is typically from a higher-fitness virus. Under this scenario, the local 
replication of viruses that are ultimately lost would have to be very limited and not sufficient 
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to induce an adaptive immune response (that is, seroconversion without systemic infection). 
Both scenarios strongly suggest that T/F viruses are the only variants that have sustained 
replication at the site of transmission and that all other variants are lost very quickly (FIG. 
3).
Understanding when the bias toward transmission of higher-fitness variants occurs can also 
reveal additional information about the factors limiting transmission. For example, biased 
transmission of viruses closer to the consensus sequence was more severe in female-to-male 
transmission than in male-to-female transmission, with infection of females allowing the 
transmission of lower-fitness genotypes and transmission to males more strongly favouring 
higher-fitness variants87. Exceptions to this pattern arise when a female donor has a higher 
viral load or when male recipients recently had a genital ulcer or inflammation. Under these 
conditions, lower-fitness variants have an increased probability of being transmitted to 
males. Similarly, selection for reduced glycosylation of the surface Env protein is stronger in 
female-to-male transmission than in male-to-female transmission29. Together, these 
studies29,87 suggest that infection of the first cell and subsequent spread to other cells may 
be more difficult in males than in females, but that amplifying factors can overcome these 
difficulties to increase the probability of lower-fitness variants being transmitted (BOX 1).
This initial stage of viral replication in the GT of newly infected individuals has also been 
suggested to induce an antiviral state through interaction with the innate immune system, 
and that this antiviral state could inhibit viral replication and select for interferon-α (IFNα) 
resistance. Indeed, recent studies examining T/F IMCs have reported that they have 
enhanced IFNα resistance71,97. However, at least some of the genetic determinants that 
define IFNα sensitivity in T/F viruses are CTL-escape mutations97 and may also reduce 
fitness. Therefore, it is difficult to know whether transmission directly selects for IFNα-
resistant viruses or whether IFNα resistance is a by-product of selection for increased viral 
fitness. Although IFNα is generally thought to limit transmission, this interpretation is 
complicated by questions about whether these factors inhibit or promote transmission and 
whether they are expressed early enough to influence transmission at all. In SIV-infected 
macaques, vaginal transmission results in rapid induction of pro-inflammatory cytokines (for 
example, tumour necrosis factor (TNF), macrophage inflammatory protein 1α (MIP1α) and 
interleukin-6 (IL-6)) that may quickly recruit target cells to the mucosal tissue, whereas peak 
production of IFNα and IFNβ occurs later98. These complications are further illustrated by 
an additional SIV–macaque experiment indicating that high levels of IFNα initially blocked 
transmission, whereas continued exposure to high levels of IFNα reduced the expression of 
antiviral proteins, allowing macaques to become infected and experience increased disease 
severity99. Thus the timing of the IFN effect determines whether the induced inflammatory 
response controls or enhances the infection.
Factors involved in the establishment of systemic infection
While many questions persist about the viral factors involved in transmission and replication 
in the GT, even less is known about whether factors that influence the ability of HIV-1 to 
replicate in specific cell types and other tissues could influence the establishment of 
systemic infection and the seeding of infection in other compartments in the body. For 
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example, an analysis of a small number of viruses suggested that transmission selects for 
T/F viruses with increased affinity for α4β7 integrin, which is expressed on some CD4+ T 
cells100. This gut-homing integrin can retain T cells in the gut-associated lymphoid tissue 
(GALT)101, where HIV-1 is known to replicate very rapidly. However, an analysis of a 
much larger panel of pseudotyped viruses did not detect a difference in the ability of an 
α4β7-specific antibody to block infection of viruses with the Env protein of T/F viruses 
compared with viruses expressing the Env protein of viruses taken from chronic infection65, 
suggesting that transmission does not select for viruses with an increased affinity for α4β7. 
These observations are supported by a recent study showing that most Env proteins, 
including those expressed by T/F viruses, are unable to efficiently bind α4β7 (REF. 102). By 
contrast, the sequence motif that binds α4β7 is over-represented in several South African 
subtype C lineages of HIV-1 relative to other clades103, therefore making it difficult to 
determine whether this motif has been selected in these lineages to increase α4β7 binding or 
is simply an ancestral sequence and has not been selected to increase α4β7 binding. The 
potential role of this integrin in infection was shown with the ability of an antibody directed 
against α4β7 to protect macaques from infection104. Furthermore, when animals treated with 
the α4β7-specific antibody became infected, they maintained CD4+ T cell counts in their 
blood and GALT that were significantly higher than those of infected, untreated animals. 
Although it is unclear whether transmission selects for viruses with an increased ability to 
bind α4β7 integrin, there is encouraging information that blocking this receptor could 
become a method of pre-exposure prophylaxis (PrEP; see below).
As most transmission events occur with a single HIV-1 variant, it is not possible to use 
genetic diversity to assess the early seeding of different compartments. However, the 
simultaneous transmission of multiple viruses provides an opportunity to investigate viral 
preference for some compartments. Surprisingly, at early stages during acute infection, some 
transmitted viral lineages can be largely absent in the blood but present in the cerebral spinal 
fluid or the central nervous system, suggesting that it is possible for multiple viruses to be 
transmitted and for some of these to be sequestered in at least one compartment and not be 
readily detected in the blood105,106. Although the extent to which this happens in other 
compartments and how this affects the establishment of the systemic infection are unknown, 
these data suggest that compartment-specific factors can influence how the systemic 
infection unfolds. Molecularly tagged SIV variants that can be used as an artificial swarm107 
will be a useful tool to address this question in the macaque model, although it must be kept 
in mind that even low-dose challenges in the macaque model represent a transmission 
frequency that is 10–100-fold higher than that seen in humans.
Bottlenecks inform prevention strategies
HIV prevention can be divided into behavioural and biological approaches, although these 
clearly overlap. Perhaps the greatest attention has been given to keeping HIV-negative 
people uninfected through safer sex that involves reliable condom usage, monogamy and 
avoidance of concurrent (that is, overlapping) partnerships, and health-seeking behaviour 
that leads to detection and treatment of STIs (reviewed by REF. 108). As noted above, 
untreated STIs cause inflammation that seems to reduce the ‘fitness barrier’ in 
transmission87 and lead to a larger average number of variants transmitted4. However, 
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attempts to reduce HIV-1 incidence in the general population by mass treatment of STIs 
have generally been unsuccessful109.
Biological interventions include circumcision and the use of antiretroviral agents and 
vaccines. Male circumcision leads to large and sustained reduction in HIV-1 acquisition110. 
This observation demonstrates that either the cells in the foreskin are highly susceptible to 
HIV-1 infection or the environment created by the foreskin increases susceptibility to 
infection.
In recent years, antiviral agents have been deployed in two ways to stop HIV-1 transmission. 
First, antiviral agents have been used as treatment, as effective treatment of an infected 
person reduces transmission probability in both heterosexual couples49,111 and MSM 
couples112 to a negligible level. Second, antiviral agents have been used as PrEP for men 
and women at high risk of HIV-1 infection. Currently, the combination of tenofovir 
disoproxil fumarate and emtricitabine (Truvada; Gilead) is approved for this purpose in the 
United States, but access outside of the United States is largely limited to clinical trials or 
demonstration projects; other drugs are in development for oral, injectable or topical usage 
as PrEP. As with ‘treatment as prevention’, the anti viral agents must be present in sufficient 
concentration to eliminate all potential T/F viruses from establishing a sustained infection. 
Studies of non-human primates suggest that these target cells are at or near the genital 
mucosal surfaces113, but more distant cells throughout the female reproductive tract 
(including the ovaries) may be exposed to virus and infected114.
Vaccines offer the most important hope for the constraint of HIV-1, and the success of a 
vaccine depends entirely on the immunity evoked being able to eliminate potential T/F 
viruses. Currently, there are three ways in which an HIV-1 vaccine might work alone or in 
combination: by priming CD8+ T cells to eliminate the initial cells infected by the T/F virus; 
by eliciting antibodies that use antibody-dependent cytotoxic means to kill infected cells 
(which is apparently the way in which the RV144 vaccine reduced HIV-1 incidence115); or 
by eliciting BNAbs that will neutralize the T/F virus. The success of each of these 
approaches depends on the ability of host defences to interact effectively with the T/F 
viruses. There are now specific examples of the importance of this interaction in the 
detection of genetic sieving of founder/breakthrough variants in the context of vaccine trials. 
In the RV144 trial, there was an association between the generation of antibodies to variable 
region 1 (V1) and V2 and protection from infection115, and there was a similar correlation in 
the sieving of specific sequences in V1 and V2 of breakthrough viruses in the vaccine 
arm116. These are both indications of selective pressure on this region due to prior exposure 
to the vaccine116. Similarly, selective pressure against T cell epitopes was detected in 
breakthrough virus in the context of the STEP vaccine trial117. An analysis of breakthrough 
virus in a vaccine trial using the SIV/macaque system demonstrated selection against 
neutralization-sensitive viruses in the challenge stock that carried a two amino acid 
signatures in Env118, again showing that prior immunization is able to apply selective 
pressure on the challenge virus.
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Thirty years of research have helped to clarify many of the details about how HIV-1 is 
transmitted. Of particular importance is the recent realization that transmission involves both 
stochastic and fitness bottlenecks that act both in the donor and in the recipient (FIG. 1). In 
the donor, bottlenecks are observed when viruses seed the donor GT (FIG. 2) and in the 
transmission fluid (FIG. 3). In the recipient, bottlenecks occur as the virus crosses the 
mucosal membrane or when it replicates in the recipient GT (FIG. 3). These bottlenecks 
ensure that sexual exposure to HIV-1 only occasionally generates a systemic infection, and 
when transmission does occur it usually involves a single viral genotype. Furthermore, these 
studies reveal information about points of transmission vulnerability that may be addressed 
by prevention strategies.
Future prevention efforts will build on these successes and insights. Antiretrovirals with 
long half-lives or slow-release formulations are being developed to ensure that antiretroviral 
drugs are maintained at high enough concentrations to be effective PrEP agents119. The 
potential role of endogenous lectins could be enhanced with the introduction of potent 
exogenous lectins, such as components in microbicides120. Furthermore, the induction of 
BNAbs by vaccination or gene therapy could create more stringent bottlenecks in the 
exposed person, which could further lower the probability of viral transmission. Finally, 
large-scale studies that are amenable to the genetic and phenotypic analysis of the T/F virus 
will continue to offer important evidence of selective pressure short of complete protection 
that can inform future efforts.
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Glossary
Retrovirus A member of the family Retroviridae. Retroviruses use reverse 
transcriptase to convert their single-stranded RNA genome 
into double-stranded DNA, which is subsequently integrated 
into the host genome. The integrated proviral genome may be 
transcribed, translated and assembled into new virions
Lentivirus Genus of the family Retroviridae that includes HIV and simian 
immunodeficiency virus (SIV)
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(T/F virus). The virus that forms a systemic infection after 
being transferred from an infected individual to an uninfected 
individual. HIV-1 infections are typically established from a 
single T/F virus
env Gene encoding the HIV-1 Env glycoprotein. This protein is 
cleaved into two subunits (gp120 and gp41), which are non-
covalently bound as heterodimers and organized as trimers on 
the virion surface. Env glycoproteins facilitate virus binding to 
and fusion with host cells
Compartmentalized 
lineages
Virus variants found outside the blood that are genetically 
distinct from variants in the blood. Compartmentalized 
lineages evolve after many generations of independent 
replication in a tissue or compartment
Transmission pairs HIV-1 donors and the recipient that each infected. Studies of 
transmission pairs are useful for examining many aspects of 
transmission biology, including factors that influence the 
probability of transmission and whether transmission 
bottlenecks select for specific viral phenotypes
Neutralizing antibodies Antibodies that inactivate infectious agents after recognizing 
antigens on their surface
Lectins Carbohydrate-binding proteins capable of neutralizing viruses 
by binding glycans on the viral surface
Glycosylation The host process of attaching glycans to proteins. 
Glycosylation of HIV-1 Env has the effect of shielding 
epitopes on Env from antibody binding
HIV subtypes Group M HIV-1 contains multiple lineages, termed subtypes
Autologous donor 
antibodies
Antibodies that are produced by the same individual who 
produced the viruses that they are neutralizing. May inhibit 
transmission by neutralizing viruses in the transmission fluid
Heterologous 
antibodies
Antibodies that are produced by an individual different from 
the one who produced the viruses that they are neutralizing
Pseudotyped viruses Viruses produced in vitro using a method that allows the 
researcher to control the specific Env proteins expressed on 
the surface of the virion
Infectious molecular 
clones





Viral variants that carry mutations in viral proteins that allow 
viruses to avoid detection by CTL. These mutations can reduce 
viral replicative fitness
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Interferon-α (IFNα). A cytokine whose expression is rapidly upregulated 
after virus exposure to signal cells to create an antiviral 
environment. IFNα can reduce HIV-1 replication
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Relationship between viral fitness and transmission
The probability that an infection will die out (that is, will not be transmitted to new cells) 
is predicted by the virus's basic reproductive rate, R0, which is an estimate of the number 
of cells that will be infected from a single infected cell121. On average, infections will be 
lost when R0 <1, and will be sustained and spread when R0 >1. Viral lineages may differ 
in their R0 owing both to stochastic factors that reduce replication of all viral lineages 
(for example, low target cell density) and to specific viral phenotypes that increase viral 
replication (for example, resistance to interferon-α (IFNα)). The bias toward 
transmission of high-fitness viruses87 suggests that most HIV-1 infected cells die out in 
the early days of the infection and do not contribute to a systemic infection (R0 <1; see 
the figure, dashed red line). Analyses of T/F viruses also indicate that HIV-1 replicates 
exponentially early in infection3, and this corresponds to a rapid increase in both R0 (see 
the figure, solid red line) and viral load (see the figure, solid blue line). This rapid 
replication reduces the proportion of cells that are susceptible to infection and stimulates 
a CD8+ T cell-mediated immune response that kills infected cells (cytotoxic T 
lymphocyte (CTL) response), which are two factors that reduce the R0 and eventually 
cause it to rapidly decline until it is less than 1. The combination of R0 <1 and death of 
infected cells generates a precipitous drop in viral load. The subsequent emergence of 
viral mutants that can escape CD8+ T cell-mediated killing (CTL-escape mutants) allows 
R0 to rebound to steady-state, at which point the average infected cell will generate one 
additional infected cell (R0 = 1), and the viral load is maintained at set point (set point 
viral load (SPVL)). The timing of these events and the SPVL are probably determined by 
several factors, including the host immune response and the fitness of the transmitted 
virus.
As noted, R0 at steady state is 1, meaning that each infected cell gives rise to another 
infected cell. However, the SPVL varies dramatically between people, from <50 copies 
per ml of viral RNA in elite controllers to >100,000 copies per ml in rapid progressors. 
These differences can be achieved either by each cell producing different numbers of 
virus particles in different people, or by different numbers of cells being infected at 
steady state in different people. The latter explanation seems more likely, given that 
SPVL is associated with the rate of disease progression122. These data justify the interest 
in studying the viral genetics of SPVL, especially the idea that each viral lineage includes 
a genetic component that is, in part, responsible for setting the SPVL in the host. Indeed, 
recent studies suggest that there is some intermediate SPVL that maximizes transmission, 
and viruses that help achieve that SPVL will be selected on a population basis123,124. 
Other studies have analysed the link between phylogenetic relatedness of T/F viruses and 
SPVL125,126. To date, these approaches have revealed a wide range of values for the 
contribution of the viral genotype to determining the SPVL and thus this remains an area 
of active interest.
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Figure 1. The transmitted/founder virus is shaped by multiple genetic bottlenecks
Chronically infected individuals have extremely diverse HIV-1 populations in their blood. 
Some viruses from the blood seed the genital tract of the donor, where the resulting viral 
population is less diverse than in the blood and is often dominated by a few clonally 
amplified variants. It is unknown whether replication in the genital tract selects for specific 
phenotypes. Viruses sampled from the donor genital tract are present in the transmission 
fluids (cervicovaginal mucus, semen or rectal secretions). These fluids may contain proteins 
that enhance (for example, semen-derived enhancers of virus infection) or reduce (for 
example, cytokines, chemokines, antimicrobials, lectins and autologous antibodies) viral 
infectivity. Differential sensitivity to these proteins could select for specific viral 
phenotypes. The vast majority of viruses within the transmission fluid do not penetrate the 
genital or rectal mucosa of the recipient. Damage due to sexually transmitted infections or 
intercourse can increase the ability of viruses to penetrate the mucosa. Most of the viruses 
that are able to infect the recipient genital tract have a low reproductive rate (R0<1) owing to 
low densities of target cells, low viral fitness or susceptibility to host defences (such as 
phagocytosis or production of interferons) and will not contribute to the systemic infection. 
Typically, when a systemic infection is established after sexual exposure to HIV-1, the 
initial viral population in the recipient's blood will be genetically homogeneous because it 
was established from a single viral genotype (the transmitted/founder virus) that was able to 
replicate in the recipient genital tract. On progression to the chronic stages of infection, 
infected individuals display extremely diverse HIV-1 populations in their blood.
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Figure 2. Compartmentalization of genital tract-specific viral lineages
HIV-1 populations in the blood are genetically diverse during chronic infection, but genital 
tract (GT)-specific lineages can be either homogeneous or diverse. a. Clonally amplified 
viruses are produced when one or a few cells (most likely T cells) are infected with very 
similar viruses. Phylogenetic analyses illustrate that clonally amplified viruses that are 
present in the GT (blue) are much less diverse than viruses that are present in the blood (red, 
orange and pink). b. Viral replication in the GT for many generations can produce diverse, 
GT-specific lineages (blue and green) that are phylogenetically distinct from viruses that are 
present in the blood (red, orange and pink). These diverse lineages may have adapted to 
replication in different cell types (such as macrophages) and/or evolved independently in 
different parts of the GT.
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Figure 3. Selection of transmitted/founder virus phenotypes
Transmitted/founder (T/F) HIV-1 viruses may be enriched for phenotypes that increase the 
probability of transmission. a. Viruses may have a low probability of being transmitted if 
they are sensitive to autologous antibodies present in the transmission fluids, such as semen 
or cervicovaginal mucus. b. Highly glycosylated viruses may also have a lower probability 
of being transmitted if they are bound by lectins in the transmission fluid. c. Glycans on the 
surface of viruses may restrict their migration through the transmission fluid. d–f. In the 
genital submucosa of the recipient, viruses may have a reduced probability of transmission if 
their Env protein is poorly adapted to entering cells in that tissue (part d). Similarly, a virus 
may have a reduced probability of transmission if it replicates slowly because it has a low-
fitness genotype or it preferentially infects target cells that do not replicate viruses rapidly 
(for example, macrophages and resting CD4+ T cells). In this case, the basic reproductive 
rate of the virus (R0, which is an estimate of the number of cells that will be infected from a 
single infected cell) will be lower than 1 and the virus will be lost (part e). By contrast, the 
probability of transmission may be increased if a virus replicates rapidly because it has a 
high-fitness genotype or an ability to preferentially infect target cells that rapidly amplify 
virus (for example, activated CD4+ T cells). In this case, the R0 of the virus will be higher 
than 1 and the virus can establish an infection and will eventually be present in the blood of 
the recipient (part f).
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Figure 4. Characteristics of transmitted/founder viruses
The dfferent cell types that are available for infection by HIV-1 transmitted/founder (T/F) 
viruses in the genital tract of the recipient differ greatly in their surface expression of the 
CD4 receptor and of the C-C chemokine receptor type 5 (CCR5) or C-X-C chemokine 
receptor type 4 (CXCR4) co-receptors. For example, CD4+ T cells express much higher 
densities of CD4 than do macrophages. Importantly, memory CD4+ T cells express both the 
CCR5 and the CXCR4 co-receptors, but for simplicity reasons, only one of the co-receptors 
is displayed in each cell. a. Most viral lineages have adapted to replicating in CD4+ T cells. 
These T cell-tropic viruses are inefficient at entering cells expressing low levels of CD4 
(such as macrophages) and require high levels of CD4+ for entry (such as those expressed by 
CD4+ T cells)64. T cell-tropic viruses can be further divided by whether they use the CCR5 
or the CXCR4 co-receptor. Most T/F viruses use the CCR5 co-receptor3,29, making them R5 
T cell-tropic. These viruses are frequently transmitted to new individuals. b. A few HIV-1 
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lineages have been identified, mostly in the central nervous system of people at end-stage 
disease, that primarily replicate in macrophages. These macrophage‑tropic viruses are able 
to enter cells expressing low levels of CD4. However, no macrophage-tropic T/F viruses 
have been reported, suggesting that these viruses are not transmitted to new individuals. c. 
Some T cell-tropic viruses can use the CXCR4 co-receptor, making them X4 T cell-tropic. 
These viruses are transmitted occasionally.
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